Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Basilea Pharmaceutica's Enterprise Value is CHF710.4 Mil.
Basilea Pharmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was CHF55.1 Mil. Therefore, Basilea Pharmaceutica's EV-to-FCF for today is 12.89.
The historical rank and industry rank for Basilea Pharmaceutica's EV-to-FCF or its related term are showing as below:
XSWX:BSLN'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.67 Med: -5.37 Max: 197.24
Current: 13.09
During the past 13 years, the highest EV-to-FCF of Basilea Pharmaceutica was 197.24. The lowest was -19.67. And the median was -5.37.
XSWX:BSLN's EV-to-FCF is ranked better than 55.14% of 321
companies
in the Biotechnology industry
Industry Median: 18.01
vs XSWX:BSLN: 13.09
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Basilea Pharmaceutica's PE Ratio (TTM) for today is calculated as:
Basilea Pharmaceutica's share price for today is CHF64.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF4.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's EV-to-FCF falls into.
Basilea Pharmaceutica's current Enterprise Value is CHF710.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was CHF55.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a EV-to-FCF of 12.89 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #144 out of 321 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Basilea Pharmaceutica's EV-to-FCF too high?
Basilea Pharmaceutica's current EV-to-FCF is 12.89. The Biotechnology industry median EV-to-FCF is 18.01. Basilea Pharmaceutica's value of 12.89 is 28.4% below this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #144 out of 321 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #144 out of 321 companies for EV-to-FCF. This puts Basilea Pharmaceutica in the upper half of its industry. The industry median EV-to-FCF is 18.01. Basilea Pharmaceutica's value of 12.89 is 28.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.01, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current EV-to-FCF of 12.89 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current EV-to-FCF is 12.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF57.28, compared to a current price of CHF64.50 — trading 12.6% above its estimated fair value. The current EV-to-FCF is 12.89 and 28.4% below the Biotechnology industry median of 18.01. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current EV-to-FCF is 12.89 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued.
The current stock price of CHF64.50 is trading 12.6% above its estimated GF Value™ of CHF57.28.
GuruFocus considers Basilea Pharmaceutica to be Modestly Overvalued.
Key valuation signals for XSWX:BSLN:
EV-to-FCF: 12.89
GF Value™: CHF57.28 vs. price of CHF64.50 (12.6% above fair value)
Industry Position: 28.4% below the Biotechnology median (#144 of 321)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score
Get the complete analysis for XSWX:BSLN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
